Literature DB >> 22257148

Role of modelling and simulation: a European regulatory perspective.

Siv Jönsson1, Anja Henningsson, Monica Edholm, Tomas Salmonson.   

Abstract

Modelling and simulation (M&S) of clinical data, e.g. pharmacokinetic, pharmacodynamic and clinical endpoints, is a useful approach for more efficient interpretation of collected data and for extrapolation of knowledge to the entire target population. This type of documentation is included in the majority of marketing authorization applications for new medicinal products. This article summarizes the current status of regulatory review with respect to the role of M&S in Europe from the perspective of the Swedish Medical Products Agency. At present, regulatory bodies in Europe encourage the application of the M&S approach during drug development. However, there is a lack of consensus and transparent guidance documents. The main regulatory usage is in the evaluation of dose choices in sub-populations and as support for the dosing regimen in general. The regulatory review of conestat alfa illustrates how the dose recommendation was revised during the approval procedure based on M&S information. A survey of marketing authorization applications for new medicinal products approved in 2010 revealed that the use of the information gained from M&S documentation varies with respect to both regulatory review and the applicants' presentation of the data in the submitted dossier. Increased utilization and broadened application of M&S is anticipated in pharmaceutical development, where one area of focus is medicines for paediatric patients. Accordingly, the regulatory agencies will need to increase their capability to assess and utilize this type of information, and an interactive process among regulatory agencies is warranted to provide more unified regulatory assessment and guidance. Moreover, applicants are encouraged to expand on the usage of exposure-response models to map the systemic exposure range that yields safe and efficacious treatment and to improve the presentation of the gained knowledge in summary documents of the marketing authorization applications.

Entities:  

Mesh:

Year:  2012        PMID: 22257148     DOI: 10.2165/11596650-000000000-00000

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  33 in total

Review 1.  Pharmacokinetics/pharmacodynamics in drug development: an industrial perspective.

Authors:  P Chaikin; G R Rhodes; R Bruno; S Rohatagi; C Natarajan
Journal:  J Clin Pharmacol       Date:  2000-12       Impact factor: 3.126

2.  Model-based drug development: strengths, weaknesses, opportunities, and threats for broad application of pharmacometrics in drug development.

Authors:  Jeffrey D Wetherington; Marc Pfister; Christopher Banfield; Julie A Stone; Rajesh Krishna; Sandy Allerheiligen; Dennis M Grasela
Journal:  J Clin Pharmacol       Date:  2010-09       Impact factor: 3.126

3.  Model-based drug development survey finds pharmacometrics impacting decision making in the pharmaceutical industry.

Authors:  Julie A Stone; Christopher Banfield; Marc Pfister; Stacey Tannenbaum; Sandy Allerheiligen; Jeffrey D Wetherington; Rajesh Krishna; Dennis M Grasela
Journal:  J Clin Pharmacol       Date:  2010-09       Impact factor: 3.126

4.  Getting the Dose Right: report from the Tenth European Federation of Pharmaceutical Sciences (EUFEPS) conference on optimizing drug development.

Authors:  Donald R Stanski; Malcolm Rowland; Lewis B Sheiner
Journal:  J Pharmacokinet Pharmacodyn       Date:  2005-11-07       Impact factor: 2.745

Review 5.  Pharmacokinetics/Pharmacodynamics and the stages of drug development: role of modeling and simulation.

Authors:  Jenny Y Chien; Stuart Friedrich; Michael A Heathman; Dinesh P de Alwis; Vikram Sinha
Journal:  AAPS J       Date:  2005-10-07       Impact factor: 4.009

6.  Model-based drug development: the road to quantitative pharmacology.

Authors:  Liping Zhang; Vikram Sinha; S Thomas Forgue; Sophie Callies; Lan Ni; Richard Peck; Sandra R B Allerheiligen
Journal:  J Pharmacokinet Pharmacodyn       Date:  2006-06-13       Impact factor: 2.745

Review 7.  Role of modeling and simulation in pediatric investigation plans.

Authors:  Efthymios Manolis; Tariq Eldirdiry Osman; Ralf Herold; Franz Koenig; Paolo Tomasi; Spiros Vamvakas; Agnes Saint Raymond
Journal:  Paediatr Anaesth       Date:  2011-01-18       Impact factor: 2.556

8.  An evaluation of the integration of pharmacokinetic and pharmacodynamic principles in clinical drug development. Experience within Hoffmann La Roche.

Authors:  B G Reigner; P E Williams; I H Patel; J L Steimer; C Peck; P van Brummelen
Journal:  Clin Pharmacokinet       Date:  1997-08       Impact factor: 6.447

9.  Application of clinical trial simulation to compare proof-of-concept study designs for drugs with a slow onset of effect; an example in Alzheimer's disease.

Authors:  Peter Lockwood; Wayne Ewy; David Hermann; Nick Holford
Journal:  Pharm Res       Date:  2006-08-12       Impact factor: 4.200

Review 10.  Clinical pharmacokinetic/pharmacodynamic and physiologically based pharmacokinetic modeling in new drug development: the capecitabine experience.

Authors:  Karen S Blesch; Ronald Gieschke; Yuko Tsukamoto; Bruno G Reigner; Hans U Burger; Jean-Louis Steimer
Journal:  Invest New Drugs       Date:  2003-05       Impact factor: 3.850

View more
  7 in total

1.  Influence of covariate distribution on the predictive performance of pharmacokinetic models in paediatric research.

Authors:  Chiara Piana; Meindert Danhof; Oscar Della Pasqua
Journal:  Br J Clin Pharmacol       Date:  2014-07       Impact factor: 4.335

2.  Translational Modeling and Simulation in Supporting Early-Phase Clinical Development of New Drug: A Learn-Research-Confirm Process.

Authors:  Dongyang Liu; Yi Zhang; Ji Jiang; John Choi; Xuening Li; Dalong Zhu; Dawei Xiao; Yanhua Ding; Hongwei Fan; Li Chen; Pei Hu
Journal:  Clin Pharmacokinet       Date:  2017-08       Impact factor: 6.447

Review 3.  Applications of pharmacometrics in the clinical development and pharmacotherapy of anti-infectives.

Authors:  Ashit Trivedi; Richard E Lee; Bernd Meibohm
Journal:  Expert Rev Clin Pharmacol       Date:  2013-03       Impact factor: 5.045

4.  Good Practices in Model-Informed Drug Discovery and Development: Practice, Application, and Documentation.

Authors:  S F Marshall; R Burghaus; V Cosson; S Y A Cheung; M Chenel; O DellaPasqua; N Frey; B Hamrén; L Harnisch; F Ivanow; T Kerbusch; J Lippert; P A Milligan; S Rohou; A Staab; J L Steimer; C Tornøe; S A G Visser
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2016-03-14

5.  Modeling and simulation to optimize the design and analysis of confirmatory trials, characterize risk-benefit, and support label claims.

Authors:  S F Marshall; R Hemmings; F Josephson; M O Karlsson; M Posch; J-L Steimer
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2013-02-27

6.  Modeling and simulation in clinical pharmacology and dose finding.

Authors:  A Staab; E Rook; M Maliepaard; L Aarons; C Benson
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2013-02-27

7.  Dose-finding methods for Phase I clinical trials using pharmacokinetics in small populations.

Authors:  Moreno Ursino; Sarah Zohar; Frederike Lentz; Corinne Alberti; Tim Friede; Nigel Stallard; Emmanuelle Comets
Journal:  Biom J       Date:  2017-03-21       Impact factor: 2.207

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.